Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Nalbuphine extended release - Trevi Therapeutics

Next Previous
Drug Profile

Nalbuphine extended release - Trevi Therapeutics

Alternative Names: Nalbuphine ER; Nalbuphine extended-release; PW-4142; T 111

Latest Information Update: 22 Jul 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Penwest Pharmaceuticals
  • Developer Endo Pharmaceuticals; MentiNova; Rutgers; Trevi Therapeutics
  • Class Antitussives; Morphinans; Opioid analgesics; Small molecules
  • Mechanism of Action Opioid kappa receptor agonists; Opioid mu receptor antagonists; Opioid receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II/III Cough; Prurigo nodularis; Pruritus
  • Preclinical Drug-induced dyskinesia
  • Discontinued Pain

Most Recent Events

  • 23 Jul 2019 Trevi Therapeutics in collaboration with Parexel plans the CANAL phase II trial for Cough in patients comorbid with idiopathic pulmonary fibrosis in United kingdom, (NCT04030026)
  • 15 Jul 2019 Trevi Therapeutics suspends a phase I pharmacokinetic trial in patients with heaptic impairment in USA (NCT04020016)
  • 12 Jul 2019 Trevi Therapeutics temporarily suspends phase I trial evaluating abuse potential in Canada (NCT04018664)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Legal

Back to top